ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology


Business Summary

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2021 KRWUSD
Gross Profit784,969.49M685.46M
Operating income537,309.40M469.20M
Income before tax547,429.45M478.03M
Net income393,589.46M343.69M
Diluted EPS5,886.125.14
Dividends Per Share00
Total Assets7,970.01B6,704.53M
Total liabilities2,978.90B2,505.91M
Total equity4,991.10B4,198.61M
Operating cash flow454,596.21M396.97M
Currency in KRWCurrency in USD

Historical Data

 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 464,629.33M 535,805.80M 701,591.85M 1,164.77B 1,568.00B
Gross Profit 122,304.94M 130,544.55M 230,536.76M 469,262.42M 784,969.49M
Operating income 65,979.40M 55,678.74M 92,084.47M 293,299.68M 537,309.40M
Income before tax -115,994.75M 302,975.83M 82,495.19M 283,759.85M 547,429.45M
Net income -96,972.11M 224,109.19M 202,904.09M 240,974.79M 393,589.46M
EBITDA 135,905.62M 147,129.29M 224,627.48M 436,474.55M 699,098.05M
Diluted EPS -1,450.60 3,351.42 3,034.42 3,603.77 5,886.12
Dividends Per Share 0 0 0 0 0
Total Assets 7,183.09B 5,980.40B 5,911.62B 6,424.20B 7,970.01B
Total liabilities 3,206.64B 1,824.94B 1,557.17B 1,825.41B 2,978.90B
Total equity 3,976.45B 4,155.46B 4,354.45B 4,598.78B 4,991.10B
Operating cash flow 149,816.32M 36,787.30M 10,153.61M 202,090.02M 454,596.21M
 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 410.99M 486.86M 601.61M 987.19M 1,369.24M
Gross Profit 108.18M 118.62M 197.68M 397.71M 685.46M
Operating income 58.36M 50.59M 78.96M 248.58M 469.20M
Income before tax -102.60M 275.30M 70.73M 240.49M 478.03M
Net income -85.77M 203.63M 173.98M 204.23M 343.69M
EBITDA 120.21M 133.69M 192.61M 369.92M 610.48M
Diluted EPS -1.28 3.04 2.60 3.05 5.14
Dividends Per Share 0 0 0 0 0
Total Assets 6,709.72M 5,359.74M 5,111.87M 5,913.83M 6,704.53M
Total liabilities 2,995.32M 1,635.54M 1,346.51M 1,680.39M 2,505.91M
Total equity 3,714.39M 3,724.20M 3,765.36M 4,233.43M 4,198.61M
Operating cash flow 132.52M 33.42M 8.70M 171.27M 396.97M

Valuation Measures

Dec 2021
Operating margin34.26%
Profit margin25.10%

Key executives

  • President, Chief Executive Officer & Director: John Chongbo Rim
  • Head-Finance & Vice President: Doyoung Heo
  • Managing Director & Head-Process Technology: Yong-Ho An
  • Head-Compliance Support: Hyung-Woo Moon
  • Executive Vice President: Kyu-Sung Lee


  • Samsung C&T Corp. (43.0%)
  • Samsung Electronics Co., Ltd. (31.2%)
  • National Pension Service of Korea (5.6%)
  • Invesco Advisers, Inc. (1.0%)
  • The Vanguard Group, Inc. (0.6%)
  • BlackRock Fund Advisors (0.6%)
  • Samsung Asset Management Co., Ltd. (0.4%)
  • Norges Bank Investment Management (0.2%)
  • Fidelity Management & Research Co. LLC (0.2%)
  • Mirae Asset Global Investments Co., Ltd. (0.2%)

Contact Details

Related Companies

  • Samsung Biologics America, Inc.
  • Samsung BioLogics Co., Ltd. ESOA
  • Samsung Romania


  • Lonza Group AG
  • Wuxi Biologics (Cayman) Inc.
  • FUJIFILM Holdings Corp
  • PanGen Biotech, Inc.
  • EirGenix Inc
  • Binex Co., Ltd
  • Celltrion, Inc.
  • Bukwang Pharmaceutical Co., Ltd.
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences, Inc.
  • EPIRUS Biopharmaceuticals, Inc.
  • Greenwich LifeSciences, Inc.
  • Kodiak Sciences, Inc.
  • PharmAbcine Inc.
  • PharmGen Science, Inc.
  • Prestige Biologics Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Reyon Pharmaceutical Co., Ltd.
Last Updated on 27 Jan, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more